Predictors of disability worsening in clinically isolated syndrome

被引:40
作者
Jokubaitis, Vilija G. [1 ]
Spelman, Tim [2 ]
Kalincik, Tomas [1 ]
Izquierdo, Guillermo [3 ]
Grand'Maison, Francois [4 ]
Duquette, Pierre [5 ]
Girard, Marc [5 ]
Lugaresi, Alessandra [6 ]
Grammond, Pierre [7 ]
Hupperts, Raymond [8 ]
Cabrera-Gomez, Jose [9 ]
Oreja-Guevara, Celia [10 ]
Boz, Cavit [11 ]
Giuliani, Giorgio [12 ]
Fernandez-Bolanos, Ricardo [13 ]
Iuliano, Gerardo [14 ]
Lechner-Scott, Jeannette [15 ]
Verheul, Freek [16 ]
van Pesch, Vincent [17 ]
Petkovska-Boskova, Tatjana [18 ]
Fiol, Marcela [19 ]
Moore, Fraser [20 ]
Cristiano, Edgardo [21 ]
Alroughani, Raed [22 ]
Bergamaschi, Roberto [23 ]
Barnett, Michael [24 ]
Slee, Mark [25 ]
Vella, Norbert [26 ]
Herbert, Joseph [27 ]
Shaw, Cameron [28 ]
Saladino, Maria Laura [29 ]
Amato, Maria Pia [30 ]
Liew, Danny [31 ,32 ]
Paolicelli, Damiano [33 ]
Butzkueven, Helmut [1 ,2 ]
Trojano, Maria [33 ]
机构
[1] Univ Melbourne, Dept Med RMH, Parkville, Vic 3052, Australia
[2] Royal Melbourne Hosp, Dept Neurol, Parkville, Vic 3050, Australia
[3] Hosp Univ Virgen Macarena, Seville, Spain
[4] Hop Charles LeMoyne, Neuro Rive Sud, Quebec City, PQ, Canada
[5] Hop Notre Dame de Bon Secours, Montreal, PQ H2L 4K8, Canada
[6] Univ G DAnnunzio, Dept Neurosci & Imaging, MS Ctr, Chieti, Italy
[7] Ctr Readaptat Deficience Phys Chaudiere Appalache, Levis, PQ, Canada
[8] Orbis Med Ctr, Sittard, Netherlands
[9] CIREN, Havana, Cuba
[10] Univ Hosp San Carlos, Madrid, Spain
[11] Karadeniz Tech Univ, Trabzon, Turkey
[12] Osped Macerata, Macerata, Italy
[13] Hosp Univ Virgen de Valme, Seville, Spain
[14] Osped Riuniti Salerno, Salerno, Italy
[15] John Hunter Hosp, Newcastle, NSW, Australia
[16] Groene Hart Ziekenhuis, Gouda, Netherlands
[17] Clin Univ St Luc, B-1200 Brussels, Belgium
[18] JZU Clin Neurol, Skopje, Macedonia
[19] FLENI, Buenos Aires, DF, Argentina
[20] McGill Univ, Jewish Gen Hosp, Montreal, PQ H3T 1E2, Canada
[21] Hosp Italiano Buenos Aires, Buenos Aires, DF, Argentina
[22] Amiri Hosp, Kuwait, Kuwait
[23] Neurol Inst IRCCS Mondino, Pavia, Italy
[24] Brain & Mind Res Inst, Sydney, NSW, Australia
[25] Flinders Univ & Med Ctr, Adelaide, SA, Australia
[26] Mater Dei Hosp, Msida, Malta
[27] NYU, Langone Med Ctr, New York, NY USA
[28] Geelong Hosp, Geelong, Vic, Australia
[29] INEBA, Buenos Aires, DF, Argentina
[30] Univ Florence, Dept Neurol, Florence, Italy
[31] Univ Melbourne, Melbourne EpiCtr, Melbourne, Vic, Australia
[32] Melbourne Hlth, Melbourne, Vic, Australia
[33] Univ Bari, Dept Basic Med Sci Neurosci & Sense Organs, Bari, Italy
基金
英国医学研究理事会;
关键词
RELAPSING MULTIPLE-SCLEROSIS; PLACEBO-CONTROLLED TRIAL; INTERFERON BETA-1A; FOLLOW-UP; GLATIRAMER ACETATE; NATURAL-HISTORY; DOUBLE-BLIND; PROGRESSION; MRI; MS;
D O I
10.1002/acn3.187
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: To assess demographic, clinical, magnetic resonance imaging, and treatment exposure predictors of time to 3 or 12-month confirmed disability worsening in clinically isolated syndrome (CIS) and early multiple sclerosis (MS). Methods: We utilized the MSBase Incident Study (MSBasis), a prospective cohort study of outcome after CIS. Predictors of time to first 3 and 12-month confirmed expanded disability status scale worsening were analyzed using Cox proportional hazards regression. Results: About 1989 patients were analyzed, the largest seen-from-onset cohort reported to-date. A total of 391 patients had a first 3-month confirmed disability worsening event, of which 307 were sustained for 12 months. Older age at CIS onset (adjusted hazard ratio: aHR 1.17, 95% 1.06, 1.30), pyramidal (aHR 1.45, 95% CI 1.13, 1.89) and ambulation (HR 1.60, 95% CI 1.09, 2.34) system dysfunction, annualized relapse rate (aHR 1.20, 95% CI 1.18, 1.22), and lower proportion of observation time on treatment were associated with 3-month confirmed worsening. Predictors of time to 12-month sustained worsening included pyramidal system dysfunction (Hazard ratio: aHR 1.38, 95% CI 1.05, 1.83), and older age at CIS onset (aHR 1.17, 95% CI 1.04, 1.31). Greater proportion of follow-up time exposed to treatment was associated with greater reductions in the rate of worsening. Interpretation: This study provides class IV evidence for a strong protective effect of disease-modifying treatment to reduce disability worsening events in patients with CIS and early MS, and confirms age and pyramidal dysfunction at onset as risk factors.
引用
收藏
页码:479 / 491
页数:13
相关论文
共 42 条
[1]   A longitudinal study of abnormalities on MRI and disability from multiple sclerosis [J].
Brex, PA ;
Ciccarelli, O ;
O'Riordan, JI ;
Sailer, M ;
Thompson, AJ ;
Miller, DH .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (03) :158-164
[2]   How effective are disease-modifying drugs in delaying progression in relapsing-onset MS? [J].
Brown, M. G. ;
Kirby, S. ;
Skedgel, C. ;
Fisk, J. D. ;
Murray, T. J. ;
Bhan, V. ;
Sketris, I. S. .
NEUROLOGY, 2007, 69 (15) :1498-1507
[3]   MSBase:: an international, online registry and platform for collaborative outcomes research in multiple sclerosis [J].
Butzkueven, H. ;
Chapman, J. ;
Cristiano, E. ;
Grand'Maison, F. ;
Hoffmann, M. ;
Izquierdo, G. ;
Jolley, D. ;
Kappos, L. ;
Leist, T. ;
Poehlau, D. ;
Rivera, V. ;
Trojano, M. ;
Verheul, F. ;
Malkowski, J-P .
MULTIPLE SCLEROSIS, 2006, 12 (06) :769-774
[4]   Effect of early interferon treatment on conversion to definite multiple sclerosis:: a randomised study [J].
Comi, G ;
Filippi, M ;
Barkhof, F ;
Durelli, L ;
Edan, G ;
Fernández, O ;
Hartung, HP ;
Seeldrayers, P ;
Sorensen, PS ;
Rovaris, M ;
Martinelli, V ;
Hommes, OR .
LANCET, 2001, 357 (9268) :1576-1582
[5]   Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome [J].
Comi, Giancarlo ;
Martinelli, Vittorio ;
Rodegher, Mariaemma ;
Moiola, Lucia ;
Leocani, Letizia ;
Bajenaru, Ovidiu ;
Carra, Adriana ;
Elovaara, Irina ;
Fazekas, Franz ;
Hartung, Hans-Peter ;
Hillert, Jan ;
King, John ;
Komoly, Samuel ;
Lubetzki, Catherine ;
Montalban, Xavier ;
Myhr, Kjell-Morten ;
Preziosa, Paolo ;
Ravnborg, Mads ;
Rieckmann, Peter ;
Rocca, Maria A. ;
Wynn, Daniel ;
Young, Carolyn ;
Filippi, Massimo .
MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (08) :1074-1083
[6]   Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process [J].
Confavreux, C ;
Vukusic, S ;
Adeleine, P .
BRAIN, 2003, 126 :770-782
[7]   Risk of multiple sclerosis following clinically isolated syndrome: a 4-year prospective study [J].
D'Alessandro, Roberto ;
Vignatelli, Luca ;
Lugaresi, Alessandra ;
Baldin, Elisa ;
Granella, Franco ;
Tola, Maria Rosaria ;
Malagu, Susanna ;
Motti, Luisa ;
Neri, Walter ;
Galeotti, Massimo ;
Santangelo, Mario ;
Fiorani, Laila ;
Montanari, Enrico ;
Scandellari, Cinzia ;
Benedetti, Maria Donata ;
Leone, Maurizio .
JOURNAL OF NEUROLOGY, 2013, 260 (06) :1583-1593
[8]   Prognostic indicators for long-term disability in multiple sclerosis patients [J].
Damasceno, Alfredo ;
Von Glehn, Felipe ;
Brandao, Carlos Otavio ;
Damasceno, Benito Pereira ;
Cendes, Fernando .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2013, 324 (1-2) :29-33
[9]  
DUQUETTE P, 1995, NEUROLOGY, V45, P1277
[10]   Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial [J].
Ebers, G. C. ;
Traboulsee, A. ;
Li, D. ;
Langdon, D. ;
Reder, A. T. ;
Goodin, D. S. ;
Bogumil, T. ;
Beckmann, K. ;
Wolf, C. ;
Konieczny, A. .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2010, 81 (08) :907-912